• Pathogenetic understanding of conservative uterine leiomyoma treatment

Pathogenetic understanding of conservative uterine leiomyoma treatment

HEALTH OF WOMAN. 2016.5(112):121–123 
 

Pathogenetic understanding of conservative uterine leiomyoma treatment 
 

Scherbina M. O., Lipko O. P., Potapova L. V., Shcherbina I. M., Mertsalova O. V.

Kharkiv national medical University

 

The article presents current views on the development of the most common disease of the female reprodactive system – uterine leiomyoma. In the pathogenesis of its occurrence are increasingly focused on the role of prolactin, as well as homeostasis of sex steroids, cholesterol, lipoproteins.


The objective: optimization of the conservative treatment of uterine leiomyoma with the inclusion to the complex of therapeutic measures aimed at reducing production of prolactin and cholesterol.


Patients and methods. It was examined and treated 72 patients with uterine leiomyoma, who were divided into two clinical groups. The I group includs 34 patients who received hormone therapy, the II group – 38 patients, who in addition to hormone therapy in complex treatment received agonists of the central and peripheral D2 dopamine receptors and omega-3-polyunsaturated fatty acids. Generally accepted clinical and laboratory tests were conducted among all patients Prolactin levels, total cholesterol, lipoproteins of low density and triglycerides were also studied.


Results. Patients with uterine leiomyoma by comparison with the control had higher level of prolactin, lipoproteins of low density and cholesterol. A significant decrease of prolactin level and total cholesterol were showed in group 2 after a combination treatment.


Conclusions. Hormonal and agonists central and peripheral D2 dopamine receptors and omega-3-polyunsaturated fatty acids Therapy increased the efficiency of l treatment of uterine leiomyoma.


Key words: uterine leiomyoma, prolactin, cholesterol, lipoproteins and low density, dopamine receptor agonists, omega-3 polyunsaturated fatty acids.


REFERENCES

1. Severin ES, Aleynikova TD, Avdeeva DV, Volkova NP i dr. 2011. Biohimiya. Pod red. ES Severina. M:779.

2. Vihlyaeva EM, Palladiyu GA. 1982. Patogenez, klinika i lechenie miomyi matki. Kishenev:236.

3. Kantemirova ZR, Torchinov AM, Zhigulina TA. 2010. Steroidnyie gormonyi, mioma matki i narusheniya funktsii pecheni, patogenez, perspektivyi lecheniya. Lechaschiy vrach. M. 3:26–39.

4. Radzinskiy VE, Maslyannikov MN, Pavlova EA, Kardanova VV. 2013. Vozmozhnosti terapii sochetaniya miomyi matki i dobrokachestvennyih displaziy molochnyih zhelez. Akusherstvo i ginekologiya. M. 4:44–46.

5. Sidorova I, Zayratyants O, Levanov S. 2004. Rol faktorov rosta i ekstratsellyulyarnogo matriksa v patogeneze prostoy i proliferiruyuschey leyomiomyi matki. Lechaschiy vrach. M. 1:32–34.

6. Tihomirov AL, Lubnin DL. 2006. Mioma matki. M, MIA:174.

7. Shilyaev AYu. 2005. Fibromioma matki. Ginekologiya 7;1:65–70.

8. Yarmolinskaya MI, Dolinskiy AK, Kogan IYu. 2013. Mioma matki. Etiologiya, patogenez, printsipyi diagnostiki. Spb:78.

9. McDonell DP, Clevenger B et al. 2013. The mechanism of action of steroid hormones, a new twist to and old tale. J.Clin.Pharmacol. 33(12):1165–72. http://dx.doi.org/10.1002/j.1552-4604.1993.tb03916.x